QLF 32004
Alternative Names: QLF-32004Latest Information Update: 08 Sep 2022
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 29 Aug 2022 700344493 - CTP Push (NCT05108779): updated Intro, KDM, DevT & added relevant HE
- 10 Nov 2021 Preclinical trials in Solid tumours in China (SC)
- 10 Nov 2021 Qilu Pharmaceutical plans a phase Ia trial for Solid tumours (Late stage disease) in China (Parenteral, Injection) (CTR20212629) (NCT05108779)